Large integration of royalty platforms

Ligand Pharmaceuticals (LGND), a leading aggregator of biotech royalties, has reached a definitive agreement to acquire competitor Xoma Royalty (XOMA) for $739 million. The transaction will be executed as an all‑cash purchase at $39 per share, representing roughly a 14% control premium over Xoma’s 30‑day volume‑weighted average price. Through the acquisition, Ligand will obtain more than 120 royalty assets spanning various clinical stages, substantially expanding its portfolio. The deal is viewed as a large‑scale integration that aligns with the current biotech investment trend of diversifying away from single‑pipeline risk and favoring stable cash‑flow streams.

Synergy from core commercial assets

The acquisition immediately gives Ligand royalty rights to three marketed drugs that generate strong cash flow: Roche’s (ROG) age‑related macular degeneration therapy Vabysmo (faricimab), Day One’s pediatric low‑grade glioma treatment Ojemda (tovorafenib), and Zevra’s (ZVRA) Niemann‑Pick disease therapy Miplyffa (arimoclomol). Notably, blockbuster Vabysmo is projected to achieve annual sales of CHF 4.1 billion in 2025, which should materially bolster Ligand’s financial stability. The growth of these products is expected to serve as a core driver of Ligand’s royalty revenue over the next decade.

Pipeline expansion and legal rights

Xoma’s value extends beyond its marketed products to include late‑stage pipeline assets and litigation‑related rights. The portfolio now incorporates 14 late‑stage assets, among them Takeda’s (TAK) Phase 3 anti‑CD38 antibody candidate mezagitamab. In addition, Xoma shareholders will receive a conditional price‑adjustment right (CVR) that entitles them to 75% of the net proceeds from the judgment and settlement of Janssen’s (JNJ) patent litigation concerning Tremfya (guselkumab). This structure is seen as a clever way to separate the upside potential of the lawsuit from its inherent uncertainty.

Efficient cost integration and outlook

CEO Todd Davis said the integration of the two platforms is expected to generate cost‑saving synergies approaching 100%. Because the royalty business does not require large manufacturing or clinical development infrastructure, Ligand can manage Xoma’s portfolio with its existing organization. This will substantially reduce SG&A expenses, maximize margin, and enable Ligand to pursue additional small‑ to mid‑size royalty acquisitions in the $25 million to $60 million range more aggressively. Ultimately, the merger is projected to cement Ligand’s dominant position in the royalty market, which serves as an alternative financing channel for biotech companies.